Halozyme Therapeutics (HALO) 10-K2022 FY Annual report

Filed: 21 Feb 23, 4:27pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: AB, absence, acetate, acute, adrenal, affirmative, AG, agent, allegedly, Allergan, allergic, AMI, analyst, ANDA, Androderm, Androgel, API, assemble, assembled, assembly, attendance, auto, Aveed, avoid, awaken, Axiron, baby, BALLAD, banker, baseline, batch, bathroom, billable, bioequivalence, birth, BofA, brought, CA, Camino, caproate, capsule, Cardinal, caregiver, Carlo, CDE, channel, choice, Chugai, ComDel, comfort, constituent, contact, CRO, customizable, cycle, deficiency, Del, deliverable, desmopressin, device, dispensing, diversify, dosage, double, easy, El, element, enanthate, Encompassing, Endo, endocrinology, entrusting, epidermal, epinephrine, EpiPen, escalation, Ewing, exceeding, exenatide, expenditure, expiry, Fast, FCA, Ferring, field, finite, Forsteo, Fortesta, Gel, glucocorticoid, gMG, handling, hearing, Humanitarian, hybrid, hydrocortisone, hydroxyprogesterone, hypogonadism, hypogonadotropic, idiopathic, Idorsia, IMA, improperly, incomplete, inconsistent, infarction, injector, injured, input, insufficiency, insufficient, intramuscular, IPL, Jabil, JATENZO, jeopardized, Jersey, Jr, juvenile, Kabi, Kilroy, Kyzatrex, lack, largest, lazertinib, liable, Lipocine, lived, macroeconomic, Makena, Mar, maternal, McKesson, melanoma, methotrexate, migraine, Minnesota, Minnetonka, mL, mode, Monte, Mumford, myocardial, nasal, needle, NextPharma, night, nighttime, NOCDURNA, nocturia, nocturnal, noncompliance, NP, NSCLC, occupied, official, oil, oral, OTREXUP, Otter, output, outsource, Overnight, Owen, parenteral, pathway, pattern, PCI, PDUFA, pemphigoid, pen, permissible, Perrigo, physician, pivotal, PK, platinum, polyarticular, polyradiculoneuropathy, polyuria, possession, predominant, pregnant, premarket, preterm, progestin, properly, prove, putative, question, QuickShot, RA, Realty, rebate, recalcitrant, refile, refinance, renew, rescinded, rescue, resection, retail, revocation, rheumatoid, sample, Sandoz, sBLA, Scandinavian, scrutiny, Seismic, seize, selatogrel, Sharp, simulation, size, SOFR, sooner, speed, spontaneously, stable, statistical, streamlined, sublicense, sublingual, substance, sumatriptan, sunshine, supplemental, swing, syringe, tablet, tangible, teriparatide, Testim, Testopel, testosterone, Teva, threatening, TLANDO, Tolmar, tongue, tooling, topline, transdermal, TRT, truthful, unapproved, unchanged, undecanoate, undiscounted, unresectable, untreated, unwilling, uptake, urinate, urination, urine, usage, USP, USPTO, Vai, verify, viability, VIBEX, VYVGART, warehouse, water, Whitewater, withdrawn, XYOSTED, Ypsomed

Removed: Athyrium, awardee, body, cartilage, closely, collaborator, Connecticut, Cook, deficit, discharging, disposed, entitle, floor, GmbH, incidental, inhibitor, investigational, investor, LIBOR, LP, Modification, modified, ninety, opening, people, Pharmica, pipeline, prevalent, prospective, reacquired, reflected, Relypsa, retrospective, Road, RSA, satisfying, side, Sorrento, Subtopic, superior, supplementary, sustained, Switzerland, taxable, thousand, uneven, unknown, unregistered, Valley, visibility

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated HALO transcripts

HALO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Dated:

February 21, 2023

/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.

Helen I. Torley, M.B. Ch.B., M.R.C.P.

President and Chief Executive Officer

In connection with the Annual Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nicole LaBrosse, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Dated:

February 21, 2023

/s/ Nicole LaBrosse

Nicole LaBrosse

Senior Vice President and Chief Financial Officer